Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Boehringer Enters Asthma Market With New Indication For Spiriva Respimat

Executive Summary

Spiriva – the first long-acting muscarinic antagonist approved for asthma – wins broad indication; sales target is likely sizeable patient population with uncontrolled disease.

Advertisement

Related Content

FDA Approves GSK’s Anoro Ellipta, The First LABA/LAMA Combination

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register